The use of targeted mouse models for preclinical testing of novel cancer therapeutics

Area of Science:

• Oncology
• Translational Medicine
• Genetics

Background:

• Genetically engineered mouse models (GEMMs) are increasingly utilized in preclinical research.
• Previous models like tumor xenografts and early transgenic models have shown limited success in predicting patient therapeutic responses.
• Advancements in mouse model development offer renewed optimism for their predictive capabilities.

Purpose of the Study:

• To evaluate the predictive utility of genetically engineered cancer-prone mice in clinical applications.
• To assess the potential of novel mouse models in drug development.

Main Methods:

• Review of existing literature on tumor xenografts and transgenic cancer models.
• Analysis of recent advancements in the development of genetically engineered mouse models.
• Assessment of the potential for these models to serve as surrogates for patients in clinical trials.

Main Results:

• Historically, tumor xenografts and early transgenic models have yielded disappointing results in predicting therapeutic efficacy.
• Recent progress in mouse model technology suggests a higher standard of predictive utility is achievable.
• The expectation of GEMMs as patient surrogates requires further demonstration.

Conclusions:

• Newer generations of genetically engineered mouse models hold significant promise for improving drug development.
• Further validation is needed to confirm the predictive power of these advanced models in clinical settings.
• Optimism exists for enhanced translational value of mouse models in oncology research.